Inovio Pharmaceuticals Inc Total Liabilities
Inovio Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has total liabilities worth $77.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Inovio Pharmaceuticals Inc (1998–2024)
Total liabilities of Inovio Pharmaceuticals Inc from 1998 to 2024. This chart illustrates how Inovio Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Inovio Pharmaceuticals Inc (INO) long-term investment share to see how much of total assets are deployed in long-term investments.
Inovio Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yen Sun Technology
TWO:6275
|
Taiwan | NT$2.13 Billion |
|
Vita Life Sciences Ltd
AU:VLS
|
Australia | AU$22.03 Million |
|
Optical Cable Corporation
NASDAQ:OCC
|
USA | $20.58 Million |
|
Shimmick Corporation Common Stock
NASDAQ:SHIM
|
USA | $275.26 Million |
|
Faraday Future Intelligent Electric Inc
NASDAQ:FFIE
|
USA | $339.87 Million |
|
Shin Foong Specialty and Applied Materials Co
TW:6582
|
Taiwan | NT$330.07 Million |
|
Bms Birlesik Metal Sanayi ve Ticaret AS
IS:BMSTL
|
Turkey | TL1.10 Billion |
|
Lastminute.com NV
SW:LMN
|
Switzerland | CHF517.92 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Inovio Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Inovio Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Inovio Pharmaceuticals Inc Total Liabilities Ratios Explained
Inovio Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inovio Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual total liabilities of Inovio Pharmaceuticals Inc from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $44.69 Million | -16.62% |
| 2023-12-31 | $53.60 Million | -57.52% |
| 2022-12-31 | $126.17 Million | +31.06% |
| 2021-12-31 | $96.27 Million | +22.43% |
| 2020-12-31 | $78.63 Million | -43.25% |
| 2019-12-31 | $138.55 Million | +214.30% |
| 2018-12-31 | $44.08 Million | -1.50% |
| 2017-12-31 | $44.75 Million | -11.08% |
| 2016-12-31 | $50.33 Million | +32.77% |
| 2015-12-31 | $37.91 Million | +87.22% |
| 2014-12-31 | $20.25 Million | -42.78% |
| 2013-12-31 | $35.38 Million | +244.16% |
| 2012-12-31 | $10.28 Million | -22.38% |
| 2011-12-31 | $13.24 Million | +47.72% |
| 2010-12-31 | $8.97 Million | -53.89% |
| 2009-12-31 | $19.44 Million | -2.20% |
| 2008-12-31 | $19.88 Million | +127.46% |
| 2007-12-31 | $8.74 Million | -29.78% |
| 2006-12-31 | $12.45 Million | +125.99% |
| 2005-12-31 | $5.51 Million | +1.97% |
| 2004-12-31 | $5.40 Million | +357.27% |
| 2003-12-31 | $1.18 Million | -30.26% |
| 2002-12-31 | $1.69 Million | +1.39% |
| 2001-12-31 | $1.67 Million | +4.68% |
| 2000-12-31 | $1.60 Million | -26.83% |
| 1999-12-31 | $2.18 Million | +45.41% |
| 1998-12-31 | $1.50 Million | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more